Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000006741
Ethics application status
Approved
Date submitted
19/12/2012
Date registered
4/01/2013
Date last updated
4/01/2013
Type of registration
Prospectively registered
Titles & IDs
Public title
The impact of a core medicines list on access to medicines for palliative patients within their home environment
Query!
Scientific title
The impact of a core medicines list on access to medicines for palliative patients within their home environment
Query!
Secondary ID [1]
281701
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1137-9975
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Palliative Care
287989
0
Query!
Pain
287990
0
Query!
Dyspnoea
287991
0
Query!
noisy Breathing
287992
0
Query!
nausea and vomiting
287993
0
Query!
delirium and agitation
287994
0
Query!
Condition category
Condition code
Public Health
288373
288373
0
0
Query!
Health promotion/education
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
To provide educational support, in the form of academic detailing, to general practitioners to guide prescribing for palliative symptoms to 1 of 5 medicines: metoclopramide 10mg/2mL injection, morphine 10mg/mL injection, hyoscine butylbromide 20mg/mL injection, haloperidol 5mg/mL injection or clonazepam 1mg injection
The academic detailing will involve individual appointments with each general practitioner in the study area, to deliver consistent education messages. These will occur within a 30 minute time period and as a single visit for each practitioner.
Query!
Intervention code [1]
286238
0
Not applicable
Query!
Comparator / control treatment
This is a quality improvement study to see if we can increase the likelihood of community pharmacies to hold a range of medicines if the prescribers are aware of the types of medicines that they hold. We will compare the rates of holding these medicines prior to and after the intervention
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
288545
0
increase in the stock holding of all 5 core medicines in community pharmacies within a defined geographical area.
this will be assessed through monthly questionnaires to each of the community pharmacies. all data will be documented in a secure database.
Query!
Assessment method [1]
288545
0
Query!
Timepoint [1]
288545
0
3 months
Query!
Secondary outcome [1]
300436
0
improved communication between general practitioners , community nurses and community pharmacists about palliative patients.
All general practitioners , community nurses and community pharmacists will be asked to complete a survey that will measure their perceived communication. we have data from a previous study that only 20% of community pharmacists learned of the palliative status of a patient through a health care provider.
Query!
Assessment method [1]
300436
0
Query!
Timepoint [1]
300436
0
6 months
Query!
Eligibility
Key inclusion criteria
Patients will not be enrolled into this study
general practitioners , community nurses and community pharmacists will be voluntarily enrolled and the inclusion criteria is that they are based in the City of Victor Harbor (council zone).
Query!
Minimum age
No limit
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients will not be enrolled into this study
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
21/01/2013
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
25
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Funding & Sponsors
Funding source category [1]
286489
0
Hospital
Query!
Name [1]
286489
0
Southern Adelaide Palliative Service
Query!
Address [1]
286489
0
700 Goodwood Road
Daw Park
SA 5041
Query!
Country [1]
286489
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Kate Swetenham
Query!
Address
700 Goodwood Road
Daw Park
SA 5041
Query!
Country
Australia
Query!
Secondary sponsor category [1]
285279
0
None
Query!
Name [1]
285279
0
Query!
Address [1]
285279
0
Query!
Country [1]
285279
0
Query!
Other collaborator category [1]
277229
0
Other
Query!
Name [1]
277229
0
Southern Adelaide-Fleurieu-Kangaroo Island Medicare Local
Query!
Address [1]
277229
0
Box 1, Level 2A, Mark Oliphant Building
5 Laffer Drive
Bedford Park SA 5042
Query!
Country [1]
277229
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
288567
0
Southern Adelaide Clinical Human Research Ethics Committee
Query!
Ethics committee address [1]
288567
0
Flinders Medical Centre, Bedford Park SA 5042
Query!
Ethics committee country [1]
288567
0
Australia
Query!
Date submitted for ethics approval [1]
288567
0
Query!
Approval date [1]
288567
0
21/11/2012
Query!
Ethics approval number [1]
288567
0
024.12
Query!
Summary
Brief summary
A recent survey of community pharmacies across South Australia (unpublished) concluded that it is difficult for community pharmacies to anticipate which medicines to stock for the treatment of symptoms commonly seen in the terminal phase of a palliative illness. This information ties in with other published qualitative studies As a result, a South Australian Palliative Care Formulary Working Party formed and subsequently developed an End of Life Essential Medicines List. This list of medicines was determined following a review of the 6 most frequently encountered symptoms noted in the terminal phase of a palliative illness - nociceptive pain, agitation, nausea/vomiting, dyspnoea, delirium and noisy breathing. The final list of medications was informed by the Working Party’s experience, the Palliative Care Therapeutic Guidelines and other locally used guidelines. The Working Party settled on these medications based on their efficacy, their usefulness in managing more than one symptom and availability on the Schedule of Pharmaceutical Benefits (PBS): - Morphine 10mg/mL Injection - Haloperidol 5mg/mL Injection - Metoclopramide 10mg/2mL Injection - Hyoscine butylbromide 20mg/mL Injection -Clonazepam 1mg Injection A hub pharmacy will be selected in the Victor Harbor Statistical Local Area (SLA): postcode: 5211 The location of the hub pharmacy will be shared with all other community pharmacies within the SLA to encourage quick access to medicines. The location of the hub pharmacy will not be shared with GPs, Nursing homes or patients and their carers. This is a quality improvement initiative. The aim of this audit is to evaluate the impact of this quality improvement strategy on: -Supporting local community clinicians to provide palliative care for non-complex patients through the standardisation of prescribing; -The viability for community pharmacies to stock medicines from an end of life essential medicines list; and -The impact of having a pharmacy hub in a SLA to support prompt and efficient supply of palliative medicines.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
36706
0
Mr Paul Tait
Query!
Address
36706
0
Daw House Hospice
700 Goodwood Road
Daw Park SA 5041
Query!
Country
36706
0
Australia
Query!
Phone
36706
0
+61 478 407 877
Query!
Fax
36706
0
Query!
Email
36706
0
[email protected]
Query!
Contact person for public queries
Name
36707
0
Paul Tait
Query!
Address
36707
0
Daw House Hospice
700 Goodwood Road
Daw Park SA 5041
Query!
Country
36707
0
Australia
Query!
Phone
36707
0
+61 478 407 877
Query!
Fax
36707
0
Query!
Email
36707
0
[email protected]
Query!
Contact person for scientific queries
Name
36708
0
Paul Tait
Query!
Address
36708
0
Daw House Hospice
700 Goodwood Road
Daw Park SA 5041
Query!
Country
36708
0
Australia
Query!
Phone
36708
0
+61 478 407 877
Query!
Fax
36708
0
Query!
Email
36708
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF